RecruitingPhase 1NCT05318534

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease

Studying Cold agglutinin disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Gliknik Inc.
Principal Investigator
Jim Bush, MBChB, PhD
Fortrea Clinical Research Unit Ltd.
Intervention
GL-0719(drug)
Enrollment
70 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05318534 on ClinicalTrials.gov

Other trials for Cold agglutinin disease

Additional recruiting or active studies for the same condition.

See all trials for Cold agglutinin disease →

← Back to all trials